Democrats moved to take back control of the drug pricing conversation in the US this week, announcing a two-day House Oversight and Reform Committee hearing that will feature six pharmaceutical CEOs targeted for the high prices of a half dozen drugs. The 22 September hearing announcement follows a string of drug pricing executive orders by President Donald Trump.
The 30 September hearing will feature former Celgene Corporation CEO Mark Alles and Bristol-Myers Squibb Company CEO Giovanni Caforio to discuss cancer drug Revlimid. Teva Pharmaceutical Industries...